Mind Medicine MindMed : Corporate Presentation April 2025

Published: 2025-04-16 17:06:05 ET MNMD

Corporate Presentation

April 2025

Transformational Innovation

for Brain Health

Maintaining Momentum with Multiple Upcoming Milestones

2024

✓ $250 million in equity investment

✓ Initiation of Phase 3 program for

MM120 ODT in GAD (first patient

dosed in Phase 3 Voyage study)

✓ MM120 Phase 2b results

presented at APA Annual Meeting

✓ MM120 granted breakthrough

designation by U.S. FDA

✓ Successful end-of-phase 2

meeting with U.S. FDA supporting

pivotal trial plans

✓ MM120 ODT patent issued

covering pharmaceutical

formulation, methods of

manufacturing and treatment;

patent life through 2041

✓ MM120 ODT awarded Innovation

Passport by the U.K. MHRA

1H20252H2025

1H20262H2026

MM120-300 for GAD

Phase 3 Readout

MM120-301 for GAD

Phase 3 Readout

MM120-310 for MDD

Phase 3 Readout

Expected cash runway through key clinical readouts and into 20271

1. The Company's cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 based on our current operating plan and anticipated R&D milestones. The Company expects its cash runway to extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD.

GAD: Generalized Anxiety Disorder; MDD: Major Depressive Disorder; APA: American Psychiatric Association; ODT: Orally Disintegrating Tablet; U.K. MHRA: United Kingdom Medicines and Healthcare Products Regulatory Agency

Corporate Presentation | April 2025

Advancing Our Pipeline with Broad Therapeutic Potential

Product Candidate

Indication

Preclinical

Phase 1

Phase 2

Pivotal /

Registration

Phase 3

MM120 ODT

Generalized Anxiety

(Lysergide D-tartrate)

Disorder (GAD)1

Major Depressive

Disorder (MDD)1,2

Additional

Indication(s)2

MM402

Autism Spectrum

(R(-)-MDMA)

Disorder (ASD)1

LSD: lysergide; R(-)-MDMA: rectus-3,4-methylenedioxymethamphetamine

Corporate Presentation | April 2025

Current Standard of Care is Failing Patients with GAD and MDD

Treatment Landscape Currently

Dominated by SRIs

"It's frustrating, the trial and error, we flip a coin and try medication. It might work and you don't know how long it will take and what the side effects will be. It's not a good experience." 9

"There is lack of new drugs with a different mechanism of action and more efficacious in symptom control … you end up prescribing similar treatments from the same family." 9

- Psychiatrist

"The lack of efficacy of current treatment, the poor tolerability of current treatment. It either doesn't work, it doesn't work fast enough, or patients can't tolerate it. So…there is a clear need for something that works better, more tolerable than the current standard of care." 9

- Payer

1. Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry. (2006) 11:805-14; 2. Birkett MA, Shinday NM, Kessler EJ, Meyer JS, Ritchie S, Rowlett JK. Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice. Pharmacol Biochem Behav. 2011 Jun;98(4):544-51; 3. Zhdanava M, Pilon D, Ghelerter I, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder

in the United States. J Clin Psychiatry. 2021;82(2):20m13699. Published 2021 Mar 16; 4. APA. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Published 2010; 5. Center for Drug Evaluation and Research (CDER).

Corporate Presentation | April 2025

Major Depressive Disorder: Developing Drugs for Treatment Guidance for Industry. Food and Drug Administration. Published 2018; 6. Grenard JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States:

a meta-analysis. J Gen Intern Med. 2011 Oct;26(10):1175-82; 7. DiMatteo MR, et al.. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern

Med. 2000;160:2101-7; 8. Braund, T.A., Tillman, G., Palmer, D.M. et al. Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. Transl Psychiatry 11, 417 (2021); 9.

Proprietary MindMed Primary Market Research

SRI: serotonin reuptake inhibitor

MM120 Has the Potential to Redefine Treatment for Patients

CURRENT STATE

DESIRED FUTURE STATE

Chronic Symptom

Rapid & Durable

Suppression

Improvement

• Cycles of medication failure

•

Fast onset

•

Delayed onset

•

Single administration

•

Poor tolerability

•

Favorable tolerability

•

Low remission rate

•

High remission rates

•

Loss of efficacy

•

Durable response

•

Symptom masking

•

Restores neural pathways

Corporate Presentation | April 2025

…And Represents a Welcome Breakthrough for Providers

% of Surveyed Providers1 Agree

All psychiatric providers 2

Interventional psychiatric providers3

86%

78%

74%

62%

Availability of psychedelics for GAD and MDD

I expect psychedelic treatments to radically

will change my approach to treatment

transform the treatment of GAD and MDD

Corporate Presentation | April 2025

MM120 ODT LSD D-tartrate

Program Overview

Clinical Rationale and Mechanism of Action

Corporate Presentation | April 2025

Disclaimer

Mind Medicine (MindMed) Inc. published this content on April 16, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 16, 2025 at 21:05 UTC.